I’m seriously impressed!!! I’d love to get my hands on that!
I’ve reproduced some of Nayagam’s CV below (sourced mainly from LinkedIn and E & P website). With its early-stage pipeline of retinal and CNS disease assets, I doubt that you could find a better fit analyst for PYC.
Dr. David Nayagam
Head of Healthcare Research at Evans and Partners.
Special interest in under-researched companies with sound investment potential based on their technology.
Provides insights to institutional and wealth clients regarding these potential opportunities.
Facilitates corporate access, and helping clients access technical insights, via experience in the medical research and healthcare community.
Connects promising healthcare companies with investment capital.
Neuroscientist, electrical engineer, and clinical researcher.
As a researcher at Melbourne’s Bionics Institute, worked on the development and successful implantation of a suprachoroidal retinal prosthesis (‘Bionic Eye’ into blind patients in a world-first clinical trial, 2012- 2015.
Considered an international expert in preclinical safety studies.
Review editor for the journal, 'Frontiers in Neuroscience', lecturer, PhD supervisor and mentor.
Regular on ABC radio ('Science Commentator' for the 774 show 'Evenings') and a moderator of the world's largest scientific forum on reddit.
International publication track record in scientific, clinical, and engineering journals.
MBA, Melbourne Business School.
PYC Price at posting:
6.1¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
into blind patients in a world-first clinical trial, 2012- 2015.
(20min delay)